


# Our Pipeline

We are building a pipeline of *in vivo* and *ex vivo* therapies, as well as continuing to develop innovative modular platform capabilities.

Program	Approach	Research	Candidate Selection	IND-Enabling	Early-Stage Clinical	Late-Stage Clinical	Partner
<b>In Vivo</b>		<b>CRISPR is the therapy</b>					
NTLA-2001: Transthyretin Amyloidosis	Knockout	[Progress bar]					LEAD Intellia THERAPEUTICS REGENERON
NTLA-2002: Hereditary Angioedema	Knockout	[Progress bar]					Intellia THERAPEUTICS
NTLA-3001: AATD-Lung Disease	Insertion	[Progress bar]					Intellia THERAPEUTICS
Hemophilia B	Insertion	[Progress bar]					LEAD REGENERON Intellia THERAPEUTICS
Hemophilia A	Insertion	[Progress bar]					LEAD REGENERON Intellia THERAPEUTICS
Research Programs	Knockout, Insertion, Consecutive Edits	[Progress bar]					Intellia THERAPEUTICS
Research Programs	Various	[Progress bar]					Intellia THERAPEUTICS REGENERON**
<b>Ex Vivo</b>		<b>CRISPR creates the therapy</b>					
OTQ923 / HIX763: Sickle Cell Disease	HSC	[Progress bar]					NOVARTIS Intellia THERAPEUTICS***
NTLA-5001: Acute Myeloid Leukemia	WT-TCR	[Progress bar]					Intellia THERAPEUTICS
Solid Tumors	WT-TCR	[Progress bar]					Intellia THERAPEUTICS
Undisclosed Programs	Undisclosed	[Progress bar]					Intellia THERAPEUTICS
Other Novartis Programs	CAR-T, HSC, OSC	Undisclosed					NOVARTIS Intellia THERAPEUTICS***



\* Lead development and commercial party

\*\* Rights to certain *in vivo* targets

\*\*\* Milestones & royalties only

**CAR-T:** Chimeric Antigen Receptor T cells

**HSC:** Hematopoietic Stem Cells

**OSC:** Ocular Stem Cells

Last updated November 4, 2021